The State Children's Health Insurance Program (SCHIP) will expire September 30, 2007, unless Congress approves legislation reauthorizing this popular program offering healthcare services for children and some adults. The deadline puts this issue at the top of the Congressional agenda as an opportunity for Democratic leaders to increase public access to care. Efforts to expand coverage for children and secure the Medicare program are important to the managed care community because the legislators are eyeing "overpayments" to Medicare Advantage plans as a possible source for some $50 billion to fund SCHIP and other healthcare programs.
Democrats want to boost SCHIP's budget by at least $10 billion a year ($50 billion over five years), which they claim is needed to maintain current coverage; program expansion to more children and adults will require added funding. The Bush administration has proposed only $5 billion in annual spending and limiting the program to children in families with annual incomes less than 200% of the federal poverty level (about $38,000). State governors are pressing hard for an expanded program and for immediate relief from funding shortfalls this year.
About 6 million children are enrolled in SCHIP, which varies from state to state; several states cover children up to 300% of poverty, and New Jersey has a 350% coverage level. Health experts estimate that some 2 million additional children are eligible for the program but have not enrolled, usually because of lack of information on the program.
TOP PRIORITIES
Several other healthcare measures top the legislative priority list for Congressional leaders:
Jill Wechsler, a veteran reporter, has been covering Capitol Hill since 1994.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
Extending the Capabilities of the EHR Through Automation
August 2nd 2023Welcome back to another episode of "Tuning In to the C-Suite," where Briana Contreras, an editor of Managed Healthcare Executive, had the pleasure of chatting with Cindy Gaines, chief clinical transformation officer at Lumeon.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
Read More